REVIEW PAPER
New drugs for gout
Online publication date: 2010-04-08
Reumatologia 2009;47(6):344-347
KEYWORDS
ABSTRACT
Gout is a metabolic disorder resulting from the accumulation of sodium urate in the body due to reduced renal clearance or (less frequently) increased production of uric acid or excessive purine intake. Allopurinol, colchicine, and uricosuric drugs are routinely used to treat gout, but they are not always effective and/or well tolerated. Increasing incidence of gout in elderly patients with significant comorbidities makes the treatment even more challenging. Febuxostat, a new strong inhibitor of xanthine oxidase, is more effective than allopurinol in reducing serum urate level and is recommended for use in patients with kidney failure and those with the highest serum urate levels and tophaceous gout. Pegloticase, pegylated mammalian uricase transforming uric acid into allantoin, has proven effective in refractory gout, but high treatment costs, immunogenicity, as well as common adverse drug reactions remain a concern. Interleukin 1 (IL-1) antagonists show efficacy in treating acute gout flares.
REFERENCES (7)
1.
Chen LX, Schumacher HR. Gout: an evidence-based review. J Clin Rheumatol 2008; 14 (5 Suppl): S55-62. .
2.
Chohan S, Becker MA. Update on emerging urate-lowering therapies. Curr Opin Rheumatol 2009; 21: 143-149. .
3.
Becker MA, Schumacher HR Jr, Wortmann R, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450-2461. .
4.
Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008; 59: 1540-1548. .
5.
Sundy JS, Becker MA, Baraf HS, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study. Arthritis Rheum 2008; 58: 2882-2891. .
6.
Schumacher HR Jr. The pathogenesis of gout. Cleve Clin J Med 2008; (75 Suppl 5): S2-54. .
7.
So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9: R28.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
